Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis. (original) (raw)
Cummins, E., Asseburg, C., Punekar, Y.S., Shore, E., Morris, J., Briggs, A. 
ORCID: https://orcid.org/0000-0002-0777-1997 and Fenwick, E.L.(2011) Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis.Value in Health, 14(1), pp. 15-23. (doi: 10.1016/j.jval.2010.10.016)
Full text not currently available from Enlighten.
Publisher's URL: http://dx.doi.org/10.1016/j.jval.2010.10.016
Abstract
Infliximab represents a cost-effective treatment option well within the National Institute for Health and Clinical Excellence threshold relative to palliative care. In light of equivalent outcomes with other tumor necrosis factor α inhibitors, its position in the treatment pathway is likely to be governed by treatment cos
| Item Type: | Articles |
|---|---|
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Briggs, Professor Andrew |
| Authors: | Cummins, E., Asseburg, C., Punekar, Y.S., Shore, E., Morris, J., Briggs, A., and Fenwick, E.L. |
| Subjects: | R Medicine > R Medicine (General) |
| College/School: | College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Health Economics and Health Technology Assessment |
| Journal Name: | Value in Health |
| ISSN: | 1098-3015 |
University Staff: Request a correction | Enlighten Editors: Update this record
Deposit and Record Details
| ID Code: | 50511 |
|---|---|
| Depositing User: | Users 11867 not found. |
| Datestamp: | 18 Apr 2011 16:53 |
| Last Modified: | 22 Sep 2021 17:13 |
| Date of first online publication: | 2011 |